Real‑world study finds grade 1 CRS during CD20 bispecific therapy for follicular lymphoma is often safe at home, reducing hospital use.
Lynnette Henshaw, PharmD, BCOP
Advertisement
Articles by Lynnette Henshaw, PharmD, BCOP
A real-world study at MSK reveals promising efficacy and safety of second-generation BTK inhibitors in mantle cell lymphoma treatment, influencing future guidelines.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Accepts NDA for AD109 for Treatment of Adults With Obstructive Sleep Apnea
2
Workforce Preparation for Fall Immunization Season Starts Now
3
Clinical Forum Events Highlight the Evolving Landscape of Obesity Management
4
Antibody-Drug Conjugates and HER2 Guidelines Are Reshaping Breast Cancer Treatment
5